Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (DE:TG1N)
STUTTGART:TG1N
TG1N Stock Chart & Stats
€10.20
-€0.01(-0.52%)
At close: 4:00 PM EST
€10.20
-€0.01(-0.52%)
Day’s Range― - ―
52-Week Range€0.70 - €10.30
Previous CloseN/A
Volume0.00
Average Volume (3M)189.00
Market Cap
€335.17M
Enterprise Value€546.65M
Total Cash (Recent Filing)€14.76M
Total Debt (Recent Filing)€177.68M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Mar 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding36,406,906
10 Day Avg. Volume50
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.39
Price to Sales (P/S)12.93
P/FCF Ratio-1.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.98Price Target Upside27.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy EvidencePhase 2 diSArm data showing substantially better clinical responses and no relapses when AP-SA02 was added to standard antibiotics suggest a strong efficacy and safety profile that could justify frontline adjunct use if confirmed in a pivotal study.
Manufacturing And Platform AdvantageAn in-house cGMP phage manufacturing facility combined with an off-the-shelf phage platform provides production readiness and a practical competitive advantage that supports scaling for pivotal trials and potential commercial supply.
Regulatory EndorsementRegulatory agreement to advance AP-SA02 into a pivotal superiority trial signals meaningful agency support that reduces approval uncertainty and strengthens the pathway to potential market exclusivity.
Bears Say
Execution Risk For Pivotal TrialInitiation of the pivotal trial depends on meeting regulatory, manufacturing, and operational milestones, creating execution risk if any element is delayed or incomplete.
Funding And Dilution RiskLimited cash resources increase the likelihood of raising additional capital, which could dilute current shareholders and slow progress on development programs.
Research Objectivity ConcernsBusiness relationships between covering firms and the companies they cover create potential conflicts that may undermine the perceived objectivity of analyst reports.
Armata Pharmaceuticals News
TG1N FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was €0.70 and its highest was €10.30 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is €335.17M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2026 which is in 3 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Nov 12, 2025. The company reported -€0.646 earnings per share for the quarter, missing the consensus estimate of -€0.367 by -€0.28.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.24.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,406,906 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -€0.646 in its last earnings report, missing expectations of -€0.367. Following the earnings report the stock price went down -0.87%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in DE:TG1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.55%
12-Months-Change
Fundamentals
Return on Equity
70.29%
Trailing 12-Months
Asset Growth
-8.88%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
TG1N Stock 12 Month Forecast
Average Price Target
€12.98
▲(27.29% Upside)
Technical Analysis
Options Prices
Currently, No data available
---